| Literature DB >> 32362939 |
Karolina Młynarczyk1, Dorota Walkowiak-Tomczak1, Grzegorz P Łysiak2.
Abstract
European black elderberry naturally occurs in most of Europe and has been introduced into various parts of the world for fruit and flower production. Elderberry is rich in nutrients, such as carbohydrates, proteins, fats, fatty acids, organic acids, minerals, vitamins and essential oils. Elderberry also contains cyanogenic glycosides which are potentially toxic. Polyphenols, known for their free radical scavenging (antioxidant) activity, are the most important group of bioactive compounds present in elderberry in relatively high concentration. The high antioxidant activity of elderberry fruit and flowers is associated with their therapeutic properties. Elderberry has for a long time been used in folk medicine as a diaphoretic, antipyretic and diuretic agent. In recent years it was also found to have antibacterial, antiviral antidepressant and antitumour and hypoglycemic properties, and to reduce body fat and lipid concentration. Due to its health-promoting and sensory properties, elderberry is used primarily in food and pharmaceutical industry.Entities:
Keywords: Antibacterial and antiviral properties; Bioactive compounds; Chemical composition; Elderberry; Medicinal use; Nutritional value
Year: 2017 PMID: 32362939 PMCID: PMC7185606 DOI: 10.1016/j.jff.2017.11.025
Source DB: PubMed Journal: J Funct Foods ISSN: 1756-4646 Impact factor: 4.451
The content of phenolic compounds in elderberry fruit and flowers.
| Compound | Content in fruit | Content in flowers | Source |
|---|---|---|---|
| Total polyphenolics | 364–582 mg GAE/100 g FW, 4917–8974 mg GAE/100 g DW extr, 2684–4480 mg CAE/100 g FW, 622–672 mg CE/100 g FW | 1021.7 mg GAE/100 g FW, 3702–5333 mg CAE/100 g FW, 194 mg GAE/g dry extr | 68,25,64,74,89,16 |
| 3-caffeoylquinic acid (neochlorogenic acid) | 0.7–4.4 mg ChAE/100 g FW, 0.05–0.40 mg ChAE/g DW | 510.6 mg/kg FW, 0.8–2.4 mg/g DW | 68,59,74,17 |
| 4-caffeoylquinic acid (cryptochlorogenic acid) | 1.2–2.5 mg ChAE/100 g FW | 31.4 mg/kg FW, 0.6–1.5 mg/g DW | 68,74,17 |
| 5-caffeoylquinic acid (chlorogenic acid) | 26.4–35.9 mg ChAE/100 g FW, 0.53–1.22 mg ChAE/g DW | 10.1–20.7 mg/g DW | 68,59,17 |
| 5-caffeoylquinic acid 1 | 2779.3 mg/kg FW | 74 | |
| 5-caffeoylquinic acid 2 | 187.2 mg/kg FW | 74 | |
| 28.9 mg/kg FW | 74 | ||
| 3- | 40.5 mg/kg FW, 0.4–1.9 mg/g DW | 74,17 | |
| 5- | 80.9 mg/kg FW, 0.5–1.2 mg/g DW | 74,17 | |
| 5- | 14.6 mg/kg FW | 74 | |
| 3-feruloylquinic acid | 717.3 mg/kg FW | 74 | |
| 5-feruloylquinic acid | 370.6 mg/kg FW | 74 | |
| 1,5-Di-caffeoylquinic acid | 8.0–13.9 mg/g DW | 17 | |
| 3,4-Di-caffeoylquinic acid | 0.4–1.2 mg/g DW | 17 | |
| 3,5-Di-caffeoylquinic acid | 0.5–3.2 mg/g DW | 17 | |
| 4,5-Di-caffeoylquinic acid | 0.2–1.5 mg/g DW | 17 | |
| Dicaffeoylquinic acid 1 | 217.4 mg/kg FW | 74 | |
| Dicaffeoylquinic acid 2 | 64.6 mg/kg FW | 74 | |
| Dicaffeoylquinic acid 3 | 43.1 mg/kg FW | 74 | |
| p-Coumaroyl-caffeoylquinic acid 1 | 11.7 mg/kg FW | 74 | |
| p-Coumaroyl-caffeoylquinic acid 2 | 10.6 mg/kg FW | 74 | |
| Kaempferol dihexoside 1 | 40.2 mg/kg FW | 74 | |
| Kaempferol dihexoside 2 | 33.5 mg/kg FW | 74 | |
| Kaempferol triglycoside | 44.3 mg/kg FW | 74 | |
| Kaempferol-3-rutinoside | 0.7–1.2 mg rutin/100 g FW | 646.9 mg/kg FW, 0.2–3.0 mg/g DW | 68,74,17 |
| Kaempferol-3-glucoside | 1.05–1.79 g/100 g extr | 3.5 mg/kg FW, 1.28–2.50 g/100 g extr | 74,20 |
| Kaempferol acetylhexoside | 13.5 mg/kg FW | 74 | |
| Quercetin | 2.7–4.5 mg CGE/100 g FW, 29–60 mg/100 g FW | 107,55 | |
| Quercetin hexoside pentoside 1 | 15.1 mg/kg FW | 74 | |
| Quercetin hexoside pentoside 2 | 2.0 mg/kg FW | 74 | |
| Quercetin-3-rutinoside (rutin) | 42.6–95.6 mg rutin/100 g FW, 6–14 mg rutin/g DW, 10.86–15.39 g/100 g extr, 35.59–52.02 mg CGE/100 g FW, 1.94–6.31 mg rutin/g DW | 3265.1 mg/kg FW, 11.6–42.3 mg/g DW, 132.69–202.08 g/100 g extr | 68,107,97,74,59,17,20 |
| Quercetin-3-galactoside | 10.3 mg/kg FW | 74 | |
| Quercetin-3-glucoside (isoquercitrin) | 3.9–14.9 mg rutin/100 g FW, 1.79–3.01 g/100 g extr, 6.4–26.5 mg CGE/100 g FW, 0.11–1.08 mg rutin/g DW | 20.2 mg/kg FW, 0.4–1.9 mg/g DW, 5.37–9.67 g/100 g extr | 68,107,74,59,17,20 |
| Quercetin dihexoside | 12.2 mg/kg FW | 74 | |
| Quercetin acetylglucoside | 94.8 mg/kg FW | 74 | |
| Quercetin-3-6-acetylglucoside | 0.9–2.8 mg/g DW | 17 | |
| Isorhamnetin dihexoside | 24.5 mg/kg FW | 74 | |
| Isorhamnetin-3-rutinoside | 0.3–2.2 mg rutin/100 g FW | 888.0 mg/kg FW, 2.0–7.5 mg/g DW | 68,74,17 |
| Isorhamnetin-3-glucoside | 0.1–0.3 mg rutin/100 g FW | 61.6 mg/kg FW, 0.2–1.0 mg/g DW | 68,74,17 |
| Isorhamnetin pentoside | 3.4 mg/kg FW | 74 | |
| Isorhamnetin acetylhexoside | 37.8 mg/kg FW | 74 | |
| Catechin | 10.7 mM/kg FW | 6.8 mg/kg FW | 74,86 |
| Epicatechin | 81.3 mM/kg FW | 254.3 mg/kg FW | 74,86 |
| Procyanidin trimer | 155.6 mg/kg FW | 74 | |
| Naringenin | 734.2 mg/kg FW | 74 | |
| Total anthocyanins | 170–343 mg CGE/100 g FW, 518–1028 mg CGE/100 g FW, 408.6–1066.6 mg CGE/100 g DW, 285–1326 mg CGE/100 g extr, 39–153 mg CGE/g DW, 664–1816 mg CGE/100 g FW, 8.33–101.40 mg CSE/g DW, 1.9–20.2 g CSE/kg FW, 48.46–52.89 g/100 g extra, 602.9–1265.3 mg CGE/100 g FW, 254–841 mg/100 g FW | 68,107,97,25,53,59,20,55 | |
| Cyanidin-3-sambubioside-5-glucoside | 16.0–59.2 mg CGE/100 g FW, 14–47 mg CGE/100 g FW, 0.86–11.50 mg CSE/g DW, 19.52–53.49 mg CGE/100 g FW | 68,107,59,55 | |
| Cyanidin-3,5-diglucoside | 8.2–19.5 mg CGE/100 g FW, 0.12–5.22 mg CSE/g DW, 5–36 mg CGE/100 g FW, 7.41–23.29 mg CGE/100 g FW | 68,107,59,55 | |
| Cyanidin-3-sambubioside | 122.2–269.1 mg CGE/100 g FW, 4.62–40.30 mg CSE/g DW, 269–656 mg CGE/100 g FW, 27.05–27.70 g/100 g extr, 270.8–630.8 mg CGE/100 g FW, 15–59 mg CGE/g DW | 68,107,97,59,20,55 | |
| Cyanidin-3-glucoside | 204.6–481.4 mg CGE/100 g FW, 2.74–49.50 mg CSE/g DW, 361–1266 mg CGE/100 g FW, 21.41–25.18 g/100 g extr, 221.4–586.4 mg CGE/100 g FW, 14–78 mg CGE/g DW, 42.4–254.3 mg/100 g extr | 68,107,97,25,59,20,55 | |
| Cyanidin-3-rutinoside | 1.49–9.63 mg CGE/100 g FW, Tr | 68,107 | |
| Pelargonidin-3-glucoside | Tr | 68 | |
| Delphinidin-3-rutinoside | Tr | 68 |
* Abbreviation: GAE – gallic acid equivalents, CAE – caffeic acid equivalents, ChAE – chlorogenic acid equivalents, CGE – cyanidin-3-glucoside equivalents, CSE – cyanidin-3-sambubioside equivalents, DW – dry weight FW – fresh weight.
Bioavailability of elderberry antioxidants.
| Human subjects | Elderberry preparation | Dose | Duration | Urinary excretion | Cmax | tmax | Metabolites | References |
|---|---|---|---|---|---|---|---|---|
| 7 volunteers (3 female, 4 male) | 4 g of spray-dried elderberry juice (50 ml of fresh juice equivalent), containing 12.5% of anthocyanins | 500 mg of anthocyanins | 6 h | 0.04% of cyanidin-3-sambubioside, 0.01% of cyanidin-3-glucoside | – | – | Probable but not identified | |
| 4 female subjects | 12 mg of elderberry extract dissolved in 500 ml of water | 720 mg of anthocyanins | 24 h | 0.055% | 97.4 nmol/l | 72 min | – | |
| 7 volunteers (6 female, 1 male) | 150 ml of concentrated elderberry juice | 3569 mg of anthocyanins | 5 h | 0.053% | – | – | Glucuronide conjugates (0.003%) | |
| 8 volunteers (4 female, 4 male) | 200 ml of elderberry juice | 361 mg | 7 h | 0.033% | – | |||
| 300 ml of elderberry juice | 541 mg | 7 h | 0.038% | |||||
| 400 ml of elderberry juice | 722 mg of anthocyanins | 7 h | 0.040% | |||||
| 400 ml of elderberry juice | 2240 mg of total phenolics | 4 h | – | 16.1 mg/l | 1 h | |||
| 710 mg of anthocyanins | – | 52.6 µg/l | 1 h | |||||
| 8 male subjects | 500 mg of isotopically labelled cyanidin-3-glucoside (6,8,10,3′,5′-13C5-C3G) | 500 mg (as two 250 mg capsules) | 48 h | 5.37% | 0.14 µmol/l | 1.81 h | Phase II conjugates of C3G and cyanidin, degradants, phase II conjugates of protocatechuic acid, phenylacetic acids, phenylpropenoic acids, hippuric acid |
*abbreviation: Cmax – maximum plasma concentration, tmax – time to reach Cmax.
Medicinal potential of elderberry (Sambucus nigra) preparations – in vitro studies.
| Medicinal potential | Elderberry preparation | Results | References |
|---|---|---|---|
| Antibacterial activity | Ethanol extract of elder flowers and berries | Inhibitory activity for most of the 13 nosocomial pathogens (e.g. | |
| Aqueous extract of elder leaves | Moderate activity against | ||
| Standardized liquid extract of elderberry (Rubini®) | Reduction in the growth of | ||
| Antiviral activity | Standardized liquid extract of elderberry (Rubini®) | Reduction in the spread of the foci size of influenza B human virus, reduction in the foci of influenza A (KAN-1) human virus in Madin-Darby canine kidney cell culture (MDCK) | |
| Elderberry extract: | Inhibition of influenza A (H1N1) human virus in MDCK | ||
| concentration of 252 µg/ml | IC50 for H1N1 | ||
| concentration of 1000 µg/ml | 100% inhibition of H1N1 | ||
| Concentrated elderberry juice: | Inhibition of H1N1 in MDCK | ||
| extract concentration of 720 µg/ml | IC50 for H1N1 (samples were given during infection) | ||
| extract concentration of 3600 µg/ml | IC50 for H1N1 (samples were given immediately after infection) | ||
| Elderberry extract | Inhibition of infectious bronchitis virus (IBV) – a pathogenic chicken coronavirus. Reduction in IBV titers by several orders of magnitude, in dependence of the dose applied | ||
| Elder bark extract | High activity against feline immunodeficiency virus (FIV) – common domestic cats virus | ||
| Extract concentration of 500 µg/ml | 100% inhibition of syncytia formation | ||
| Diabetes treatment | Elder flowers extract (1 g/L) | Increase in glucose uptake, glucose oxidation and glycogenesis in mice abdominal muscles without added insulin | |
| Impact on urinary parameters | Elder flower extract in the form of capsules | No apparent inhibitory effect on uridine diphospho-glucuronosyltransferase (UGTs). IC50 values were higher than 500 µg/mL for UGTs enzymes (UGT1A1, UGT1A4, UGT1A6, UGT1A9 and UGT2B7) | |
| Antitumour activity | Elderberry extract (extract fraction including phenolic compounds, iridoid monoterpene glycosides, phytosterols and sesquiterpenes) | Prevention of the initiation and promotion of cancerogenesis stages: strong induction of quinone reductase and inhibition of cyclooxygenase-2 |
Medicinal potential of elderberry (Sambucus nigra) preparations – in vivo studies.
| Medicinal potential | Study design | Elderberry preparation | Dosage | Duration | Results | References |
|---|---|---|---|---|---|---|
| Antiviral activity | Female mice (6 weeks old) infected with influenza A virus | Concentrated elderberry juice separated in three fractions (low, medium and high molecular weight) | 2 times/day | 14 days | Suppression of the viral yield in the bronchoalveolar lavage fluids (BALFs) and lungs; increase in the level of IFV specific neutralizing antibody in the BALFs and serum and in the level of the secretory IgA in the BALFs and feces | |
| R, D-B, P-C, 60 patients (18–54 years) presenting influenza A and B symptoms | Standardized elderberry extract (Sambucol® syrup) | 15 ml, 4 times/day | 5 days | Symptoms of influenza A and B virus ebbed four days earlier in the elderberry group compared to the placebo group | ||
| R, D-B, P-C, 64 patients (16–60 years) presenting flu symptoms | Proprietary elderberry extract as lozenge (175 mg of extract in each lozenge) | 4 lozenges/day | 48 h | 28% of patients in the elderberry group were void of all flu symptoms and 60% of patients experienced a relief of some symptoms, whereas the placebo group demonstrated no improvement | ||
| Diabetes treatment | Male rats (28 weeks old) divided into four groups including diabetic rats | Polyphenolic elderberry extract | 0.040 g/kg body every 2 days | 16 weeks | Improvement of the bone mineral density and of the antioxidative capacity of serum; reduction in the body fat in diabetic rats; decrease in the lipid peroxidation level in serum; improvement of the osteoporosis status | |
| Male rats (11 weeks old) divided into four groups including type 2 diabetic rats fed a high-fat diet | Elderberry polar extract | 350 mg/kg body/day | 4 weeks | The polar extract lowered fasting blood glucose, the lipophilic extract decreased insulin secretion. Both extracts reduced insulin resistance | ||
| Elderberry lipophilic extract | 190 mg/kg body/day | |||||
| Effect on metabolic dysfunctions in obesity | Male mice (8 weeks old) divided into four groups including diet-induced obese mice | Elderberry extract (13% of anthocyanins) | 0.25% of extract (20–40 mg anthocyanins/kg body1.25% of extract (100–200 mg/kg body | 16 weeks | Both elderberry groups had a lower liver weight and serum TAG concentration, and lower serum inflammatory markers, insulin resistance and hepatic lipids compared to the control obese group; the addition of 1.25% of extract reduced liver cholesterol and PPARγ2 mRNA compared to both other obese groups | |
| Effect on cholesterol and HDL dysfunctions | Male mice (10 weeks old) in a mouse model of hyperlipidemia and HDL dysfunction | Elderberry extract (13% of anthocyanins) | 1.25% of extract (100–200 mg anthocyanins/kg body | 6 weeks | No significant differences in serum lipids between groups; reduction in aspartate transaminase and fasting glucose in the elderberry group; changes in hepatic and intestinal mRNA with an improvement in HDL function and a reduction in hepatic cholesterol levels; increase in serum paraxonase-1 arylesterase activity in the elderberry group | |
| Effect on lipid and antioxidant status | R, P-C, D-B, 34 healthy volunteers (20 males, 24 females) | 400 mg spray-dried elderberry powder in gelatinous capsules (10% of anthocyanins in each capsule) | 3 times/day | 2 and 3 weeks | No significant differences in the changes in serum lipids and vitamin A, E and β-carotene in the elderberry group were observed compared to the placebo group; a decrease in the level of vitamin C in both groups; | |
| 6 volunteers | The same | A single dose | 1 day | An increase in total anthocyanins in serum; | ||
| Effect on weight reduction | 80 participants | Elderberry juice with flower extract; tablets containing berry powder and flower extract (1 mg anthocyanins, 370 mg flavonol glycosides, 150 mg hydroxycinnamates); Tablets containing | At least 3 L of elderberry juice, 3 | 15 days | The BMI index dropped by approx. 3%, the weight fell by an average of 3.2 kg, systolic blood pressure decreased by an average of over 5% and diastolic blood pressure by 2.5% | |
| Effect on weight reduction and urinary parameters | 11 volunteers | Diluted (1:5) concentrate of elderberries (from 120 g of berries) and flowers (flower juice and extract from 3.9 g of dried flowers) | 200 ml divided into up 6 portions | 7 days | An average weight reduction was 2.6 kg; no effect on pH, hydrogen ion concentration and 24 h hydrogen excretion in urine; no effect on the solubility of stone-inducing ions | |
| Antidepressant potential | Male mice divided into six groups | 200–1200 mg/kg | – | |||
| Imipramine | 10 mg/kg |
*Abbreviation: R – randomized, D-B – double-blind, P-C – placebo-controlled.
Fig. 1Antiviral (influenza A and B) properties of elderberry fruit (Kinoshita et al., 2012, Kong, 2009, Krawitz et al., 2011, Roschek et al., 2009, Zakay-Rones et al., 2004).
Fig. 2Mechanism of action of the bioactive compounds of Sambucus nigra on influenza A virus (Roschek et al., 2009).